Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $8.3 million.

  • Lifecore Biomedical's Cash & Equivalents fell 2.33% to $8.3 million in Q2 2025 from the same period last year, while for May 2025 it was $8.3 million, marking a year-over-year decrease of 2.33%. This contributed to the annual value of $8.3 million for FY2025, which is 2.33% down from last year.
  • Lifecore Biomedical's Cash & Equivalents amounted to $8.3 million in FY2025, which was down 2.33% from $8.5 million recorded in FY2024.
  • Over the past 5 years, Lifecore Biomedical's Cash & Equivalents peaked at $19.1 million during FY2023, and registered a low of $763,000 during FY2021.
  • In the last 3 years, Lifecore Biomedical's Cash & Equivalents had a median value of $8.5 million in 2024 and averaged $11.9 million.
  • Per our database at Business Quant, Lifecore Biomedical's Cash & Equivalents surged by 1,826.44% in 2023 and then crashed by 55.68% in 2024.
  • Yearly analysis of 5 years shows Lifecore Biomedical's Cash & Equivalents stood at $763,000 in 2021, then climbed by 29.88% to $991,000 in 2022, then surged by 1,826.44% to $19.1 million in 2023, then plummeted by 55.68% to $8.5 million in 2024, then declined by 2.33% to $8.3 million in 2025.